Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery
NCT04966546Phase 1Withdrawn
- Sponsor
- The University of New Mexico
- Start
- Jun 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic subdural hematoma (CSDH) comparing Memantine with Placebo (2 arms). Primary endpoints: Spreading depolarizations and seizures at 5 days and Extended Glasgow Outcome Scale at 90 days. Planned start Jun 2022; status: withdrawn.
02
Drugs
memantine
03
Conditions
chronic subdural hematoma (CSDH)
Beyond the preview
Go deeper on NCT04966546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04966546.